Non-Armored GCC-targeting CAR-T cell therapy demonstrates significant efficacy in patients with advanced colorectal cancer [0.03%]
非武装GCC导向的CAR-T细胞疗法治疗晚期结直肠癌患者疗效显著
Qianyu Zhang,Lin Lin,Wei Wang et al.
Qianyu Zhang et al.
Purpose: This phase 1 clinical trial aims to evaluate the safety, expansion kinetics, and preliminary efficacy of non-armored, nanobody-derived GCC-targeted CAR-T cells in patients with heavily pretreated, metastatic colo...
Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer [0.03%]
肿瘤浸润淋巴细胞作为三阴性乳腺癌术后阿维鲁单抗疗效预测因素的研究
Maria Vittoria Dieci,Elisa Gasparini,Lorenzo Nicolè et al.
Maria Vittoria Dieci et al.
Purpose: We aimed to investigate the prognostic and predictive value of tumor infiltrating lymphocytes (TILs) for adjuvant immunotherapy in high-risk early TNBC. ...
Correction: A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas [0.03%]
纠正:多柔比星联合 zalifrelimab(抗 CTLA-4 抗体)和 balstilimab(抗 PD-1 抗体)治疗晚期/转移性软组织肉瘤 II 期单臂试验
Breelyn A Wilky,Katherine A Julian,Alessandra Maleddu et al.
Breelyn A Wilky et al.
HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma [0.03%]
HPV16型基因组状态可对口咽鳞癌患者疾病复发风险进行分层评估
Victor Malassigné,Julien Puech,Sandrine Imbeaud et al.
Victor Malassigné et al.
Purpose: A subset of patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma develops disease recurrence despite generally favorable outcomes. Reliable biomarkers for risk stratification remain l...
Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent Resection [0.03%]
新辅助治疗和根治性手术后的胰腺癌空间构型与疾病复发相关性研究
Luis H Cisneros,Merih D Toruner,Zafar Siddiqui et al.
Luis H Cisneros et al.
Purpose: Pancreatic ductal adenocarcinoma (PDAC) frequently recurs after neoadjuvant therapy (NT) and curative-intent resection. Although major pathologic response predicts favorable outcomes, most patients achieve only m...
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer [0.03%]
肿瘤内的免疫异质性决定了肺癌PD-(L)1阻断的疗效差异
Laura Cipriani,Davide Mascolo,Stefano Scalera et al.
Laura Cipriani et al.
Purpose: Clinical outcomes with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) range from durable disease control to rapid progression. Current biomarkers have limited ability to predict these d...
Sex Steroid Hormone Regulation of T cell Function and Anti-Tumor Immunity [0.03%]
性类固醇激素对T细胞功能和抗肿瘤免疫的调节作用
Amanda Heard,Rachel T Huynh,Christy R Hagan et al.
Amanda Heard et al.
Cancer immunotherapy treatment has revolutionized cancer care. Of the many FDA approved immunotherapies, immune checkpoint inhibitors are the most widely prescribed, given their utility in treating both solid and hematopoietic diseases and ...
Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib [0.03%]
EGFR突变的晚期肺腺癌患者一线使用奥希替尼治疗时出现EGFR扩增的临床意义分析
Alessandro Di Federico,Federica Pecci,Mark Jeng et al.
Alessandro Di Federico et al.
Purpose: With rapidly expanding treatment options for patients with EGFR-mutated non-small cell lung cancer (NSCLC), identifying biomarkers that may assist treatment selection is critical. The impact of EGFR amplification...
A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus [0.03%]
仑伐西姆单抗和托贝西姆单抗与尼伏鲁玛对比治疗晚期或转移性食管鳞细胞癌的II期生物标志物研究:一项随机试验
Lucjan Wyrwicz,Arunee Dechaphunkul,Jong-Seok Lee et al.
Lucjan Wyrwicz et al.
Purpose: The bispecific antibodies lomvastomig and tobemstomig block the immune checkpoint receptor PD-1 and either TIM-3 or LAG-3, respectively. This phase 2 study assessed their efficacy compared with nivolumab in CPI-n...
The H63D Polymorphism in the HFE Gene Promotes Aggressive Disease Phenotypes in Pancreatic Ductal Adenocarcinoma [0.03%]
铁基因H63D多态性促进胰腺导管腺癌的侵袭性疾病表型
Federica Rubbino,Luana Greco,Alessandro Scagliotti et al.
Federica Rubbino et al.
Purpose: Controversy exists regarding the association between HFE H63D polymorphism and pancreatic ductal adenocarcinoma (PDAC). This study initially assessed the frequency of H63D in PDAC patients and subsequently invest...